The Therapeutic Goods Administration has issued a fresh warning to clinicians and consumers after laboratory testing confirmed that some imported weight-loss products marketed as GLP-1 therapies are counterfeit and contain no glucagon-like peptide-1 receptor agonists
Most products are tested by third parties to ensure that the safety, quality and potency of the products are in line with the company's standards
Some who traditionally would fear injections are willing to try a weekly pen when they hear about significant weight improvements
The infusion is not recommended during pregnancy and breastfeeding, or in cases of hypersensitivity to any ingredient
doi:10.21873/cgp.20035 Schumann C, Nguyen DX, Norgard M, et al
Retatrutide is a triple agonist, activating GLP-1, GIP, and glucagon receptors simultaneously